Decompensated Cirrhosis Clinical Trial
Official title:
The Feasibility of Liver Biomarkers as Prognostic Markers in Decompensated Alcoholic Liver Disease
Fibroscan is a non invasive imaging investigation which measures liver stiffness, known to correlate well with liver scarring and cirrhosis on liver biopsy. Indocyanine green is an inert dye which is purely extracted from the blood by liver cells, and is hence an excellent marker of both liver cell function and overall liver blood flow. There is little data for either of these biomarkers regarding outcomes in alcoholic liver disease. We aim to establish the accuracy of these liver biomarkers in predicting important liver related outcomes (death, transplantation and hospital readmission with cirrhosis related consequences) in patients with severe (decompensated) alcoholic liver disease. Moreover, we will assess whether the serial measurement of biomarkers has any impact on alcohol abstinence, motivation or quality of life. Over an 18 month period, 125 consecutive hospital inpatients with decompensated alcoholic liver disease will undergo baseline biomarker measurement, routine blood and urine tests and qualitative questionnaires. These will be measured during their initial hospital admission (0 months) with subsequent repeat measurement during follow up visits at 1, 2, 4 and 6 months. Each study visit time will be in the region of 30-40 minutes to complete these investigations. The end of the study for individual patients will be patient death, liver transplantation or 6 month from study enrolment; whichever occurs first.
This is a single centre longitudinal cohort feasibility pilot study of patients with
decompensated alcoholic liver disease. We aim to recruit 125 consecutive patients with
decompensated alcoholic liver disease over an 18 month period. This number is based upon
approximately 10 admissions per month to acute liver services with decompensated alcoholic
liver disease and includes a presumed 20% dropout rate during follow up, giving a total
cohort of 100 patients. Patients will undergo a maximum of 6 months follow up following
study recruitment.
The purposes of this study are:
1. To assess the performance of diagnostic liver biomarkers (Indocyanine Green, Fibroscan
and blood and urinary biomarkers) in predicting mortality in decompensated alcoholic
liver disease.
2. To compare the diagnostic and prognostic end points of these biomarkers with existing
cirrhosis prognostic scoring systems (Child Pugh, MELD and UKELD).
3. To assess the performance of diagnostic biomarkers as a therapeutic aid to quality of
life and alcohol abstinence.
Potentially eligible patients i.e. adults with decompensated liver disease with alcohol as a
major co-factor, and acutely admitted secondary to sequelae of hepatic decompensation, will
be approached by an existing member of their clinical care team (The CI & Co-Investigators
form part of this team). Any patient who decides to take part in the study will have a
baseline inpatient study visit either on their inpatient ward or to the NDDC Biomedical
Research Unit (BRU). Subsequent follow up visits will be to the BRU.
Inclusion Criteria:
- Male or female patients 18-75 years of age
- Diagnosis of cirrhosis based upon:
- a) Histological confirmation
- b) Combination of clinical and radiological criteria
- c) Validated non invasive biomarker
- Alcohol as the primary aetiology for liver cirrhosis
- Hospital admission related to decompensated liver disease (e.g. ascites, varices,
sepsis, alcoholic hepatitis)
- Active alcohol drinking prior to index hospital admission
Exclusion Criteria:
- Grade 3 or 4 hepatic encephalopathy
- Hepatocellular carcinoma
- Active non hepatic malignancy
- Known complete portal vein thrombosis
- Alcohol abstinence at time of index hospital admission
- Pregnancy
- Active cardiac devices
The research visit will require measurement of ICG clearance, Fibroscan, blood tests, urine
tests and questionnaires. They will then be required to attend study visits at 1, 2, 4 and 6
months following the baseline study visit, after which study follow up will cease.
Patients will undergo study visits at the following intervals:
- Baseline visit (study visit 0)
- 1 month (study visit 1)
- 2 months (study visit 2)
- 4 months (study visit 3)
- 6 months (study visit 4)
The following data will be collected for the purposes of this research project at the
baseline and subsequent study visits:
- Collection of demography, anthropometry, drug history, smoking, alcohol intake, blood
pressure, full blood count, renal function, liver function, coagulation and serum
samples
- Brief abdominal examination to detect presence of moderate to severe ascites (for the
purposes of Child Pugh score measurement)
- ICG analysis
- Transient elastography (Fibroscan)
- Blood and urinary biomarkers (proteomics and metabonomics)
- Chronic Liver Disease Quality of Life Questionnaire
- Alcohol intake assessments (28 Day AUDIT tool)
- Alcohol STAR tool for qualitative assessment (to assess the influence of Fibroscan/ICG
readings on motivation, beliefs and alcohol abstinence)
Demography and history are taken as part of normal clinical care. All patients will be
offered standard follow up from both outpatient hepatology clinic and hospital alcohol
liaison services throughout the period of study.
;
Observational Model: Cohort, Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05121870 -
Treatment With Human Umbilical Cord-derived Mesenchymal Stem Cells for Decompensated Cirrhosis
|
Phase 2 | |
Recruiting |
NCT05421351 -
Immune Profile, Neuronal Dysfunction, Metabolomics and Ammonia in Therapeutic Response of HE in ACLF
|
||
Not yet recruiting |
NCT05086536 -
Re-compensation and Its Clinical Characteristics in HBV Decompensated Cirrhosis
|
||
Recruiting |
NCT03820271 -
New Prognostic Predictive Models of Mortality of Decompensated Cirrhotic Patients Waiting for Liver Transplantation
|
N/A | |
Recruiting |
NCT06134544 -
Effect of IMO on Intestinal Microbiota Translocation in Cirrhosis
|
N/A | |
Recruiting |
NCT06223893 -
CirrhoCare- Using Smart-phone Technology to Enhance Care and Access to Treatment for Cirrhosis
|
N/A | |
Completed |
NCT02219477 -
A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With Ribavirin in Adults With Genotype 1 and Ombitasvir/Paritaprevir/Ritonavir With Ribavirin in Adults With Genotype 4 Chronic Hepatitis C Virus Infection and Decompensated Cirrhosis
|
Phase 3 | |
Recruiting |
NCT05734001 -
Rotational Thromboelastometry Versus Conventional Haemostatic Tests in Children With Decompensated Cirrhosis Undergoing Invasive Procedures.
|
N/A | |
Terminated |
NCT04775329 -
Primary Prophylaxis for Spontaneous Bacterial Peritonitis
|
Phase 2/Phase 3 | |
Recruiting |
NCT04422223 -
Prospective Cohort Study of Disease and Outcomes in Cirrhosis
|
||
Recruiting |
NCT02786017 -
Injectable Collagen Scaffold™ Combined With HUC-MSCs Transplantation for Patients With Decompensated Cirrhosis
|
Phase 1/Phase 2 | |
Completed |
NCT01326949 -
Transjugular Intrahepatic Portosystemic Shunt (TIPS) for Prevention of Variceal Rebleeding in Cirrhotic Patients With Portal Vein Thrombosis
|
N/A | |
Recruiting |
NCT06396897 -
Hospital @ Home Model of Care for Cirrhosis
|
||
Not yet recruiting |
NCT06306781 -
A Clinical Trial Evaluating the Safety, Tolerability, and Preliminary Efficacy of HCL001 Cell Injection (Homologous Allogeneic Hepatocytes) in Patients With Decompensated Cirrhosis
|
N/A | |
Recruiting |
NCT05227846 -
Human Umbilical Cord-derived Mesenchymal Stem Cells for Decompensated Cirrhosis (MSC-DLC-1)
|
Phase 1 | |
Not yet recruiting |
NCT05937048 -
Coagulation Parameters With Albumin in Decompensated Cirrhosis (CoPA-D).
|
N/A | |
Active, not recruiting |
NCT03205345 -
Emricasan, a Caspase Inhibitor, for Treatment of Subjects With Decompensated NASH Cirrhosis
|
Phase 2 | |
Terminated |
NCT03462576 -
Companion Protocol for Methacetin Breath Test (MBT) in Conatus Protocol IDN-6556-17
|
||
Not yet recruiting |
NCT05224960 -
Human Umbilical Cord-derived Mesenchymal Stem Cells for Decompensated Cirrhosis (MSC-DLC-2)
|
Phase 2 | |
Terminated |
NCT04112199 -
A Study for Evaluation of BIV201 to Reduce Ascites and Complications in Patients With Cirrhosis and Refractory Ascites
|
Phase 2 |